Popular weight loss drug could cause sudden blindness – EU's health watchdog
The European Medicines Agency (EMA) has concluded that semaglutide-based medications – including Ozempic, Wegovy, and Rybelsus – increase the risk of a serious eye condition that can lead to sudden vision loss.
Following a comprehensive safety review, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) determined that non-arteritic anterior ischemic optic neuropathy (NAION) should be listed as a 'very rare' side effect of semaglutide – the main component of weight-loss and anti-diabetic drugs produced by Novo Nordisk.
The EMA's review, initiated in January 2025, analyzed data from clinical trials, post-marketing surveillance, and medical literature. Findings suggest that adults with type 2 diabetes taking semaglutide have approximately twice the risk of developing NAION compared to those not on the medication.
On Friday, the EU's health watchdog recommended updating the product information for semaglutide-containing medicines to include NAION as a potential side effect. The 'very rare' classification indicates that the condition may affect up to 1 in 10,000 users.
NAION is the second most common cause of optic nerve-related blindness after glaucoma. Patients experiencing sudden vision loss or rapidly worsening eyesight while on semaglutide are advised to seek immediate medical attention and discontinue use if NAION is diagnosed.
The Denmark-based company Novo Nordisk owns the patent on semaglutide, a GLP-1 receptor agonist used for managing type 2 diabetes and obesity. It functions by enhancing insulin secretion and promoting a feeling of fullness, thereby aiding in blood sugar control and weight management.
A recent study also indicated that Ozempic and similar medications may increase the risk of kidney cancer. However, the drugs reportedly lower the risk of more than a dozen other cancers, suggesting their overall benefit may still outweigh the hazards. Additionally, the EMA previously investigated reports of suicidal thoughts associated with semaglutide use, though no definitive causal relationship was established.
The EMA's recommendations will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP) before a final decision is adopted by the European Commission. Novo Nordisk, which was dethroned as Europe's most valuable company earlier this year, has stated its commitment to patient safety and is working with the EMA to update product labels accordingly.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Russia Today
16 hours ago
- Russia Today
Popular weight loss drug could cause sudden blindness – EU's health watchdog
The European Medicines Agency (EMA) has concluded that semaglutide-based medications – including Ozempic, Wegovy, and Rybelsus – increase the risk of a serious eye condition that can lead to sudden vision loss. Following a comprehensive safety review, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) determined that non-arteritic anterior ischemic optic neuropathy (NAION) should be listed as a 'very rare' side effect of semaglutide – the main component of weight-loss and anti-diabetic drugs produced by Novo Nordisk. The EMA's review, initiated in January 2025, analyzed data from clinical trials, post-marketing surveillance, and medical literature. Findings suggest that adults with type 2 diabetes taking semaglutide have approximately twice the risk of developing NAION compared to those not on the medication. On Friday, the EU's health watchdog recommended updating the product information for semaglutide-containing medicines to include NAION as a potential side effect. The 'very rare' classification indicates that the condition may affect up to 1 in 10,000 users. NAION is the second most common cause of optic nerve-related blindness after glaucoma. Patients experiencing sudden vision loss or rapidly worsening eyesight while on semaglutide are advised to seek immediate medical attention and discontinue use if NAION is diagnosed. The Denmark-based company Novo Nordisk owns the patent on semaglutide, a GLP-1 receptor agonist used for managing type 2 diabetes and obesity. It functions by enhancing insulin secretion and promoting a feeling of fullness, thereby aiding in blood sugar control and weight management. A recent study also indicated that Ozempic and similar medications may increase the risk of kidney cancer. However, the drugs reportedly lower the risk of more than a dozen other cancers, suggesting their overall benefit may still outweigh the hazards. Additionally, the EMA previously investigated reports of suicidal thoughts associated with semaglutide use, though no definitive causal relationship was established. The EMA's recommendations will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP) before a final decision is adopted by the European Commission. Novo Nordisk, which was dethroned as Europe's most valuable company earlier this year, has stated its commitment to patient safety and is working with the EMA to update product labels accordingly.
Russia Today
5 days ago
- Russia Today
EU mulls blocking China's access to medical device procurement
The European Union is examining the possibility of imposing restrictions on public procurement contracts across the bloc for Chinese medical device producers, Bloomberg reported on Monday, citing a person familiar with the plans. Brussels and Beijing have recently been locked in an escalating tit-for-tat stand-off over trade protectionism. Earlier this year, the European Commission (EC) said that a probe launched last year into alleged unfair Chinese trade practices had revealed that Beijing has been limiting access for EU medical devices and suppliers to the Chinese procurement market. Last month, China's Ministry of Commerce announced that its anti-dumping investigation into brandy imports from the EU – initiated in response to a probe by the bloc – had been extended due to the complexity of the case. Members of the 27-nation bloc are expected to vote on the proposed measure on Monday, June 2, the unnamed source told Bloomberg. If approved, the step would mark Brussels' first action under the International Procurement Instrument (IPI), a regulation adopted in 2022 to promote reciprocity in access to public procurement markets, the news agency noted. The IPI enables the EC to introduce a range of restrictions on companies bidding for public contracts – from score adjustments in tenders to a full ban on participation. The news comes ahead of a meeting between the two sides' top trade officials. Maros Sefcovic and Wang Wentao are reportedly expected to meet on Tuesday on the sidelines of an Organisation for Economic Co-operation and Development (OECD) ministerial conference in Paris. If adopted, the restrictions could further fuel ongoing trade tensions between the EU and China, opening a new front in disputes between both parties, each of which is also engaged in mounting trade frictions with the US.
Russia Today
04-05-2025
- Russia Today
Vucic expected at Moscow parade despite illness
Serbian President Aleksandar Vucic is expected to attend Russia's Victory Day celebrations, despite a recent health scare, Finance Minister and Deputy PM Sinisa Mali has said. The May 9 parade on Moscow's Red Square will mark the 80th anniversary of the Soviet victory over Nazi Germany in World War II. The Kremlin has invited a number of leaders from countries including Serbia, Slovakia, China, India, and Brazil. EU officials have warned member and candidate states against attending. On Friday, Vucic abruptly ended a trip to the US after experiencing chest pain during a meeting in Florida, reportedly caused by high blood pressure. He had planned to meet with the Serbian diaspora and US President Donald Trump, but returned to Belgrade and was admitted to the Military Medical Academy, according to local broadcaster RTS. Doctors said the president 'cannot be expected to return to his regular activities for several days.' Speaking on Saturday, Mali said Vucic will likely follow through with the visit. 'One thing I can say is, knowing him, considering that he is a man of his word, he gave his word that he would be there, I assume that he will keep his word. But I cannot tell you that at this moment.' Vucic was discharged from the hospital on Saturday. The Military Medical Academy confirmed that the president underwent cardiovascular and hematological diagnostics and is now in stable condition. Doctors ordered him to rest, and he has canceled all activities and obligations for the next few days. Among the EU leaders invited to the event were Hungarian Prime Minister Viktor Orban and his Slovak counterpart, Robert Fico. Hungary declined the invitation, stating that the end of World War II represented 'a bitter defeat' due to the country's alliance with Nazi Germany. Fico has confirmed his attendance. During a meeting with Vucic last month, EC Commissioner for Enlargement Marta Kos reportedly cautioned that his attendance would be held against Serbia's EU bid. Despite the pressure, Vucic said he had not changed his decision to attend the event, where a unit of the Serbian Armed Forces will also take part. Russian President Vladimir Putin praised those who accepted the invitation, calling them courageous for attending despite pressure from Brussels.
